

# WHAT'S HAPPENING WEDNESDAY

## Kansas Immunization Program

October 10, 2018

### VFC Consultant On-Call

The Consultant for October 8—12, will be Lorraine Baughman (Lorraine.baughman@ks.gov or 785-296-5592). The Consultant for October 15—19 will be Jayme Lewis (jayme.Lewis@ks.gov or 785-296-5592).



## CHIEF CHAT

Influenza vaccine is being shipped out daily as we process orders from clinic pre-books. We are reminding you that we distribute proportionally to what was originally requested and what is available in the warehouse at this time. Please understand that each clinic is different, and there are many factors that impact what vaccine is shipped and how much a clinic may receive at any given time. Factors include the presentation of vaccine that was requested compared to the presentations we have available to distribute, the capacity of the clinic to receive and have space for vaccine at any given time as well as the size of the order that was originally placed.

We received our full Flumist allocation this week, and it has been distributed as a single full order to all providers who requested it, unless you have indicated that you do not have capacity to store your full order at this time.

We also ask for your patience and understanding as we only have one employee at this time who is able to process orders. Jackie is also continuing with her other Regional Consultant duties. We ask that if

you have dissatisfaction with the current process and distribution that you contact the Kansas Immunization Program manager, Phil Griffin at 785-296-8893 or Phil.Griffin@ks.gov directly so that Jackie can dedicate her time to



getting the orders placed.

We are pleased to announce Tom Liddy has been named as the new KSWebIZ Assistant Manager. In this role, Tom is responsible for supervising the Help Desk and assisting with the overall management of the KSWebIZ. Tom started with the Kansas Immunization Program as a temporary employee working on de-duplication of records in KSWebIZ, from there he became a Help Desk technician offering support to users who called in needing assistance with functionality.



## In This Issue

### Chief Chat

Page 1

### KSWebIZ— System Down Time

Page 2

### Injection of Education

Page 3

### Vax Facts

Page 4



Like Us On  
Facebook

Thanks to all of you who LIKE our page, we are over 600 "Likes." We appreciate all of your support and hard work vaccinating Kansans from vaccine preventable diseases! We can be found by clicking on the Facebook logo or link below. Please make sure and share our posts and like our page while you are there.

<https://www.facebook.com/ImmunizeKS/>



# KSWebIZ

## System Down Time October 22

KSWebIZ will be *unavailable at 5 p.m., Monday, Oct. 22, through 8 a.m., Tuesday, Oct. 23.*

During this time, the entire KSWebIZ system will be offline and unavailable. KDHE IT department will be performing a second phase of maintenance on KSWebIZ's database server storage drives. This maintenance will require that the database servers be taken offline. KDHE plans to begin maintenance promptly at 5p.m. on Monday, Oct. 22, and continue throughout the night to ensure the servers can be restored by 8 a.m., Tuesday morning. KSWebIZ will

not be able to receive HL7 messages or be accessed while the system is offline. All HL7 messages sent during this time will need to be resubmitted once the system is restored. We know you rely on the critical information and tools in KSWebIZ. We are committed to performing this system maintenance as quickly as possible with the least amount of impact to our users. We apologize for any inconvenience this system maintenance may cause. Thank you.

### Vaccine Information Statement Current Publication Date

Anthrax	3/21/18	Tdap	2/24/15
Chickenpox	2/12/18	MMRV	2/12/18
DTaP/DT/DTP	8/24/18	Multi-vaccine	11/05/15
Hepatitis A	7/20/16	PCV 13	11/05/15
Hepatitis B	7/20/16	PPSV	4/24/15
Hib	4/2/15	Polio	7/20/16
HPV	12/2/16	Rabies	10/6/09
Influenza (LAIV4)	8/07/15	Rotavirus	2/23/18
Influenza (IIV3 or IIV4)	8/07/15	Shingles	2/12/18
Japan. enceph.	1/24/14	Smallpox	10/01/09
MenACWY	8/24/18	Td	4/11/17
MenB	8/09/16	Typhoid	5/29/12
MMR	2/12/18	Yellow fever	3/30/11



# INJECTION OF EDUCATION

The Centers for Disease Control and Prevention (CDC) recommends that everyone six months and older receive a flu vaccine, with rare exceptions. Those with a higher risk from flu complication are strongly encouraged to receive the flu shot, including children younger than five years of age (especially those under two), those 65 and older, pregnant women, and those with specific medical conditions. If you are looking for more on those with a higher risk, [\*People at High Risk of Developing Serious Flu-Related Complications\*](#) offers more information including those at higher risk due to specific medical conditions.

Who should not receive a flu vaccine? Children younger than six months of age should not receive a flu vaccine, and people with a severe, life-threatening allergy to the flu vaccine or its ingredients. You can find more information on contraindication and precautions at [\*Vaccination: Who Should Do It, Who Should Not and Who Should Take Precautions\*](#).

Children under five years of age have an increased risk of flu-related complications. The best prevention is to vaccinate not only the child, but the caregivers as well. Some children will need two doses of flu vaccine. According to the CDC, “children 6 months through 8 years getting vaccinated for the first time, and those who have only previously gotten one dose of vaccine, should get two doses of vaccine this season. All children who have previously gotten two doses of vaccine (at any time) only need one dose of vaccine this season”. You can find additional information at [\*Children & Influenza \(Flu\)\*](#). The Immunization Action Coalition has a nice flu algorithm to assist you in determining if a child needs one or two doses of flu vaccine at [\*Guide for Determining the Number of Doses of Influenza Vaccine to Give to Children Age 6 Months Through 8 Years\*](#).

With so many different brands of flu vaccine available, it is hard to keep track of the age indications and recommendations per vaccine. The CDC has a table available that not only lists the vaccine presentation (or brand), but also lists the age indications, as well as other information including if the stoppers contain latex at [\*Influenza vaccines – United States, 2018-2019 influenza season\*](#).

Studies have shown that a provider’s strong recommendation will make a difference in whether a patient will receive a vaccine. This recommendation starts when a patient checks in and ends with the patient receiving the flu vaccine. Each person who interacts with the patient has an impact on that patient and his/her willingness to receive a vaccine. [\*Tools to Prepare Your Practice for Flu Season\*](#) can help your staff in learning how to offer that strong recommendation. You are the hidden heroes in the fight against influenza!

## Quarterly Regional Public Health Meetings



Allison Alejos, Kansas Immunization Program (KIP) Vaccine For Children (VFC) Manager and Phil Griffin, Deputy Director of the Bureau of Disease Control and Prevention and KIP Program Manager will be attending the Regional Public Health meetings this quarter beginning in Chanute on Thursday, Oct. 11. The presentation will focus on KIP updates and review of the revised VFC Manual.

As with previous presentations at these meetings, we will have plenty of time for questions and look forward to hearing from you, with any comments about how we continue to strengthen the program. Having the opportunity to interact with you annually at these meetings is very valuable to us as we gather your input into our immunization partnerships.





## VAX FACTS

### FDA Expands Approval of Gardasil 9

The U.S. Food and Drug Administration today approved a supplemental application for Gardasil 9 (Human Papillomavirus (HPV) 9-valent Vaccine, Recombinant) expanding the approved use of the vaccine to include women and men aged 27 through 45 years. Gardasil 9 prevents certain cancers and diseases caused by the nine HPV types covered by the vaccine.

In 2014, the FDA approved Gardasil 9, which covers the same four HPV types as Gardasil, as well as an additional five HPV types. Gardasil 9 was approved for use in males and females ages 9 through 26 years.

The effectiveness of Gardasil is relevant to Gardasil 9 since the vaccines are manufactured similarly and cover four of the same HPV types. In a study in approximately 3,200 women 27 through 45 years of age, followed for an average of 3.5 years, Gardasil was 88 percent effective in the prevention of a combined endpoint of persistent infection, genital warts, vulvar and vaginal precancerous lesions, cervical precancerous lesions, and cervical cancer related to HPV types covered by the

vaccine. The FDA's approval of Gardasil 9 in women 27 through 45 years of age is based on these results and new data on long term follow-up from this study.

Effectiveness of Gardasil 9 in men 27 through 45 years of age is inferred from the data described above in women 27 through 45 years of age, as well as efficacy data from Gardasil in younger men (16 through 26 years of age) and immunogenicity data from a clinical trial in which 150 men, 27 through 45 years of age, received a three-dose regimen of Gardasil over 6 months.

The safety of Gardasil 9 was evaluated in about a total of 13,000 males and females. The most commonly reported adverse reactions were injection site pain, swelling, redness and headaches.

This FDA approval was announced on Oct. 5, and has not yet been reviewed by the Advisory Council for Immunization Practices (ACIP) so there is no new ACIP recommendation at this time.

## Vaccine Redistribution

Please email any additions or changes to be made on the Vaccine Redistribution lists with subject matter "Redistribution" to [kdhe.vaccine@ks.gov](mailto:kdhe.vaccine@ks.gov) or call toll free at 1-877-296-0464 [Vaccine Redistribution information and lists](#).

**REMINDERS:** Providers may place the excess doses on the KIP Redistribution list if:

1. The vaccine has a minimum of 90 days and a maximum of 365 days before the vaccine's expiration date.
  2. The ordering provider is responsible for any doses which expire on the redistribution list that have not been accepted for transfer to another VFC provider.
  3. Providers accepting vaccine from the redistribution list are responsible for using the doses once they are transferred. KIP encourages providers to accept only doses they can administer before the expiration date.
  4. The transferring and receiving provider will document these doses on their monthly reconciliation reports as transferred vaccines.
  5. Once vaccine is transferred please contact KIP to let us know so we can adjust the redistribution list by either deleting the line or by reducing the amount of doses.
  6. All vaccines must be in full boxes.
  7. The KIP Regional Immunization Consultant who is on call must be contacted prior to transferring vaccine.
  8. Providers are responsible for keeping KIP notified if there is a change in amount of doses available for redistribution.
  9. When placing an order, you may be contacted if the vaccine you are trying to order is on the redistribution list.
  10. Varicella and Proquad will not be posted on the VFC or Private Vaccine Redistribution List. Frozen Varivax vaccines are very intolerant to out of range temperatures. To prevent potential vaccine waste the KIP requests that Varivax containing vaccines not be transferred to other providers.
- For questions regarding transporting vaccine call 877-296-0464 to request assistance.